Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
News archive
News Archive Navigation
News Archive Navigation Language
December 2019
-
Key ReleaseNovartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthmaPooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication Fevipiprant was well tolerated with adverse events balanced across…
-
Media ReleaseNovartis receives positive CHMP opinion for Beovu® (brolucizumab) for the treatment of wet AMDIn two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one1 In a pre-specified secondary endpoint, fewer patients had intra-…
-
Media ReleaseNovartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results for Kisqali plus fulvestrant, reducing the risk of death by almost 30…
-
Media ReleaseNovartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world settingEfficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more heavily pretreated patients1-3 Fewer known CAR-T cell therapy…
-
Featured NewsUncovering profound and under-reported effects on people living with sickle cell disease
Results of the Sickle Cell World Assessment Survey (SWAY) highlight the impact this debilitating disease has on patients and their families.
-
Media ReleaseNovartis global survey uncovers profound and often under-reported effects on sickle cell disease patientsFindings from more than 2,000 respondents in 16 countries underscore the debilitating and under-reported effects of sickle cell disease and a pattern of not seeking care despite potentially life-…
-
A decades-long journey in blood cancer research
Novartis immunologist describes the excitement of discovering a promising new immuno-oncology (IO) target in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
-
Media ReleaseNovartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapyOnce-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versus mometasone furoate1 QMF149 showed improvement in peak…
-
Featured NewsNovartis R&D Day
Novartis shares progress in advancing its industry-leading R&D pipeline. We are uniquely positioned to deliver transformational treatments through our scale, focus on innovative medicines, diverse range of therapeutic areas and exposure to cutting-edge platforms.
-
Media ReleaseNovartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters highlighted at R&D DayUniquely positioned with global scale, focus on innovative medicines, diversification across therapeutic areas and exposure to cutting-edge platforms60 projects in Phase 2 pipeline with 10+ advancing…
-
Key ReleaseNovartis tender offer for The Medicines Company commencesBasel, December 5, 2019 — Novartis AG (NYSE: NVS) (“Novartis”) today announced that its indirect wholly-owned subsidiary, Medusa Merger Corporation, a Delaware corporation (“Purchaser”), has…
-
Featured NewsAmazon Web Services (AWS) announces strategic collaboration with Novartis to accelerate digital transformation of its business operations
We’re collaborating with AWS to build an enterprise-wide data and analytics platform to transform the way medicines are manufactured and delivered.
Pagination
- ‹ Previous page
- 1
- …
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- …
- 151
- › Next page